Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.

ABSTRACT:

Importance

Thirteen human malignant neoplasms have been identified as obesity-associated cancers (OACs), ie, the presence of excess body fat is associated with increased risk of developing cancer and worse prognosis in patients with these specific tumors. The glucagon-like peptide receptor agonist (GLP-1RA) class of pharmaceuticals are effective agents for the treatment of type 2 diabetes (T2D) and for achieving weight loss, but the association of GLP-1RAs with the incident risk of 13 OACs is unclear.

Objective

To compare the incident risk of each of the 13 OACs in patients with T2D who were prescribed GLP-1RAs vs insulins or metformin.

Design, setting, and participants

This retrospective cohort study was based on a nationwide multicenter database of electronic health

SUBMITTER: Wang L 

PROVIDER: S-EPMC11227080 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature